Fei Ding

Biochemistry, Genetics and Molecular BiologyEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study”.

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331

N/A

0.725DataRank · unranked

125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6

N/A

0.560DataRank · unranked

10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06889-0

N/A

0DataRank · unranked

8 citations

Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin +13 more